CATALOGO DEI PRODOTTI DELLA RICERCA

PILOTTO, Sara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.715
EU - Europa 9.202
AS - Asia 6.950
SA - Sud America 1.008
Continente sconosciuto - Info sul continente non disponibili 352
AF - Africa 255
OC - Oceania 17
AN - Antartide 1
Totale 27.500
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.438
RU - Federazione Russa 4.143
SG - Singapore 2.813
CN - Cina 1.813
GB - Regno Unito 1.200
IT - Italia 1.131
BR - Brasile 774
VN - Vietnam 693
HK - Hong Kong 628
DE - Germania 590
SE - Svezia 458
FR - Francia 420
IE - Irlanda 381
FI - Finlandia 316
KR - Corea 234
BD - Bangladesh 150
IN - India 149
NL - Olanda 141
CA - Canada 135
PL - Polonia 93
JP - Giappone 84
AR - Argentina 83
ID - Indonesia 74
MX - Messico 66
UA - Ucraina 62
ES - Italia 57
TR - Turchia 50
ZA - Sudafrica 45
TG - Togo 42
NG - Nigeria 41
AT - Austria 40
IQ - Iraq 38
BJ - Benin 37
CO - Colombia 31
EC - Ecuador 31
BE - Belgio 30
VE - Venezuela 28
PK - Pakistan 26
CZ - Repubblica Ceca 24
MA - Marocco 24
CL - Cile 23
LT - Lituania 18
PH - Filippine 17
UZ - Uzbekistan 17
IR - Iran 16
AU - Australia 15
CH - Svizzera 15
CR - Costa Rica 14
JM - Giamaica 14
AE - Emirati Arabi Uniti 13
KZ - Kazakistan 13
PE - Perù 13
SA - Arabia Saudita 13
TN - Tunisia 13
JO - Giordania 12
EG - Egitto 11
MY - Malesia 11
NP - Nepal 11
PY - Paraguay 11
HN - Honduras 10
KE - Kenya 10
AZ - Azerbaigian 8
LV - Lettonia 8
AM - Armenia 7
BO - Bolivia 7
CY - Cipro 7
DK - Danimarca 7
DZ - Algeria 7
GR - Grecia 7
IL - Israele 7
KG - Kirghizistan 7
PT - Portogallo 7
RO - Romania 7
AL - Albania 6
NI - Nicaragua 6
NO - Norvegia 6
SK - Slovacchia (Repubblica Slovacca) 6
UY - Uruguay 6
DO - Repubblica Dominicana 5
EU - Europa 5
PA - Panama 5
RS - Serbia 5
SN - Senegal 5
SV - El Salvador 5
TT - Trinidad e Tobago 5
AO - Angola 4
HR - Croazia 4
KH - Cambogia 4
LA - Repubblica Popolare Democratica del Laos 4
LK - Sri Lanka 4
PS - Palestinian Territory 4
SI - Slovenia 4
SY - Repubblica araba siriana 4
TW - Taiwan 4
BG - Bulgaria 3
GA - Gabon 3
HU - Ungheria 3
OM - Oman 3
TH - Thailandia 3
BH - Bahrain 2
Totale 27.107
Salva come PNG Salva come JPEG
Città #
Singapore 1.462
Moscow 1.403
Ashburn 1.374
San Jose 1.126
Dallas 1.012
Southend 901
Chandler 819
Hong Kong 616
Council Bluffs 454
Verona 395
Beijing 378
Dublin 377
The Dalles 313
Woodbridge 298
Munich 269
New York 242
Los Angeles 236
Ho Chi Minh City 220
Jacksonville 199
Ann Arbor 181
Hanoi 156
Lawrence 125
Princeton 125
Helsinki 121
Wilmington 115
Jinan 105
Santa Clara 94
São Paulo 93
London 91
Houston 87
Buffalo 85
Milan 85
Redondo Beach 75
Tokyo 73
Turku 72
Tianjin 70
Sindelfingen 64
Shenyang 60
Redmond 59
Orem 58
Frankfurt am Main 55
Meda 55
Nanjing 54
Seoul 53
Amsterdam 51
Columbus 51
Hebei 50
Montreal 50
Warsaw 50
Chicago 49
Seattle 44
Rome 43
Lomé 42
Brooklyn 40
Guangzhou 40
Lappeenranta 40
Abuja 39
Jakarta 38
Atlanta 37
Cotonou 37
Washington 36
Chennai 35
Boardman 34
Stockholm 34
Nanchang 33
San Francisco 33
Da Nang 32
Denver 32
Zhengzhou 32
Hangzhou 31
Johannesburg 31
Kent 31
Phoenix 31
Brussels 30
Changsha 30
Nuremberg 30
Haikou 29
Toronto 29
Haiphong 27
Ningbo 27
Mexico City 26
Bologna 25
Rio de Janeiro 24
Baghdad 23
Belo Horizonte 23
Dong Ket 22
Mumbai 22
Vienna 22
Shanghai 21
Biên Hòa 20
Boston 20
Paris 20
Poplar 20
Taiyuan 20
Taizhou 20
Barnet 19
City of London 19
Manchester 19
Charlotte 18
Falls Church 18
Totale 16.054
Salva come PNG Salva come JPEG
Nome #
Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients 314
"Running with cancer": A qualitative study to evaluate barriers and motivations in running for female oncological patients 258
Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis 257
ALK gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes 250
ALK/EML4 Fusion Gene May Be Found in Pure Squamous Carcinoma of the Lung 244
High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers 229
ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations 217
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 215
Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation 209
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers 202
Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitors 202
Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials 201
Deep vein thrombosis in SARS-CoV-2 pneumonia-affected patients within standard care units: Exploring a submerged portion of the iceberg 201
Adjuvant Chemotherapy For Resected Non-Small-Cell Lung Cancer: Future Perspectives For Clinical Research 200
Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer 198
A multimodal approach to cancer-related cachexia: from theory to practice 194
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic 193
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials 192
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice 191
A Feasibility Study Investigating an Exercise Program in Metastatic Cancer Based on the Patient-Preferred Delivery Mode 187
Neoadjuvant strategies for triple negative breast cancer: 'state-of-the-art' and future perspectives 184
Exercise prehabilitation in lung cancer: Getting stronger to recover faster 182
A cross-sectional study evaluating the exercise discussion with oncologist during cancer consultation: the CONNECT study 181
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 181
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives 181
Abscopal effect and resistance reversion in nivolumab-treated non-small-cell lung cancer undergoing palliative radiotherapy: a case report 180
Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations 179
Adjuvant therapy for resected early-stage small-cell lung cancer: is now time to rethink about that? 179
A propensity score analysis exploring the impact of adjuvant chemotherapy (aCT) in a multi-center series of resected early stage pure invasive lobular breast carcinoma (ILC) 179
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. 178
Gene expression profiling of lung atypical carcinoids and large cell neuroendocrine carcinomas identifies three transcriptomic subtypes with specific genomic alterations 178
Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma 174
Lung neuroendocrine tumours: deep sequencing of the four WHO histotypes reveals chromatin remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D 172
Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer 172
Tubulin inhibitors in non-small cell lung cancer: looking back and forward 171
Development of Educational Print Materials for Physical Activity in Cancer: Evaluation of Readability and Suitability 170
Integrating supportive care into the multidisciplinary management of lung cancer: we can't wait any longer 170
Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors 168
A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done 168
Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survival 168
Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting 168
A qualitative study exploring the experiences and perspectives of patients with cancer attending a 12-week exercise program 167
Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research 166
Exercise levels and preferences in cancer patients: a cross-sectional study 166
Psychological impact of Covid-19 pandemic on oncological patients: a survey in Northern Italy 166
Do immune checkpoint inhibitors need new studies methodology? 165
How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center 165
Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned 165
Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report 164
ARID1A mutational status in non-small cell lung cancer: from molecular pathology to clinical implications with a focus on the relationships with EGFR 162
MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy 162
Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors 161
A cross-sectional study exploring the perception of exercise oncology in the Italian population 160
Clinical meta-analyses of targeted therapies in adenocarcinoma. 160
Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: A 'Hard Days Night' 159
Infections and Immunotherapy in Lung Cancer: A Bad Relationship? 159
Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome 156
Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer 155
Maintenance or consolidation therapy in small-cell lung cancer: an updated systematic review and meta-analysis 155
Characterizing the immune tumor microenvironment in ALK fusion-positive lung cancer: state-of-the-art and therapeutical implications 154
Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. 153
Exercise for counteracting post-acute COVID-19 syndrome in patients with cancer: an old but gold strategy? 153
Muscle derangement and alteration of the nutritional machinery in NSCLC 152
Potential role of RICTOR copy number gain (CNG) as a key biomarker of mTOR activity: A comprehensive preclinical analysis in squamous cell lung cancer (SQLC) models 152
Multidisciplinary lifestyle intervention to manage pancreatic cancer-related cachexia: a case report 151
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 150
Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma 147
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer 147
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy 146
Effect of exercise on functional capacity in patients with advanced cancer: A meta-analysis of randomized controlled trials 146
Exploring the Association between Health-Related Physical Fitness and Quality of Life in Patients with Cancer: A Cross-Sectional Study 145
Molecular predictors of EGFR-mutant NSCLC transformation into LCNEC after frontline osimertinib: digging under the surface 145
Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives 143
Predictive and prognostic effect of computed tomography-derived body composition analysis during neoadjuvant chemotherapy for operable and locally advanced breast cancer 142
Combined Large Cell Neuroendocrine Carcinomas of the Lung: Integrative Molecular Analysis Identifies Subtypes with Potential Therapeutic Implications 142
Exercise and anemia in cancer patients: could make the difference? 142
Physical activity guidelines in oncology: a systematic review of the current recommendations 141
Impact of exercise in patients with pancreatic cancer across different treatment phases: a systematic review 141
Platelet-derived growth factor receptor inhibitors for non-small cell lung cancer: is the odyssey over? 140
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy 140
Exercise oncology: It is time to make a change 140
Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations 139
Evidence-based tailored nutrition educational intervention improves adherence to dietary guidelines, anthropometric measures and serum metabolic biomarkers in early-stage breast cancer patients: A prospective interventional study 139
Prognostic Model for Resected Squamous-Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment 138
Physical activity and exercise in lung cancer care: will promises be fulfilled? 137
PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis 137
Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer 137
Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies 136
Feasibility of a novel exercise program for patients with breast cancer offering different modalities and based on patient preference 135
Genetic and non-genetic resistance mechanisms in non-small cell lung cancer harboring (non-ALK) oncogenic fusions 135
Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity 135
Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study 135
Tracking occult pN2 disease after mediastinal dissection in early stage lung cancer. 133
Exploring the feasibility of a combined exercise program for patients with advanced lung or pancreatic cancer 132
Prognostic impact of Interleukin-8 levels in lung cancer: A meta-analysis and a bioinformatic validation 132
Implementation outcomes of early nutritional screening and referral for patients with thoracic cancers 132
Final data of an Italian multicentric survey about counseling for smoking cessation in patients with diagnosis of a respiratory disease 132
Plasmacytoid Dendritic Cell, Slan+-Monocyte and Natural Killer Cell Counts Function as Blood Cell-Based Biomarkers for Predicting Responses to Immune Checkpoint Inhibitor Monotherapy in Non-Small Cell Lung Cancer Patients 131
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model 131
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC 131
Totale 16.719
Salva come PNG Salva come JPEG
Categoria #
all - tutte 103.716
article - articoli 101.803
book - libri 0
conference - conferenze 1.155
curatela - curatele 0
other - altro 366
patent - brevetti 0
selected - selezionate 0
volume - volumi 392
Totale 207.432
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.020 0 292 8 119 39 27 31 58 46 23 95 282
2022/20232.327 144 261 206 411 196 539 19 137 262 21 97 34
2023/20241.661 59 95 158 166 212 267 99 139 39 117 229 81
2024/20254.541 230 184 209 791 148 200 201 192 708 351 435 892
2025/202614.490 848 732 1.103 2.374 3.708 849 1.305 813 1.195 925 318 320
2026/2027528 207 321 0 0 0 0 0 0 0 0 0 0
Totale 27.500